Relative bioavailability of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) administered with and without a spacer in healthy adults

P. Dorinsky (Durham, United States of America), P. Depetrillo (Baltimore, United States of America), K. Deangelis (Durham, United States of America), R. Trivedi (Durham, United States of America), M. Mo (Morristown, United States of America), S. Ballal (Morristown, United States of America), M. Gillen (Gaithersburg, United States of America)

Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Session: COPD clinical studies: bronchodilators, corticosteroids and more
Session type: Poster Discussion
Number: 3376
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Dorinsky (Durham, United States of America), P. Depetrillo (Baltimore, United States of America), K. Deangelis (Durham, United States of America), R. Trivedi (Durham, United States of America), M. Mo (Morristown, United States of America), S. Ballal (Morristown, United States of America), M. Gillen (Gaithersburg, United States of America). Relative bioavailability of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) administered with and without a spacer in healthy adults. 3376

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: